Colorectal Cancer | Specialty

Fear of Recurrence and Anxiety Lowered in Cancer Survivors After Psychological Intervention

June 3rd 2017

Psychological intervention can substantially lower fear of cancer recurrence in survivors, improving their quality of life, anxiety, and cancer-specific distress, according to a phase II randomized clinical trial presented at the 2017 ASCO Annual Meeting.

Uridine Triacetate for 5-FU or Capecitabine Toxicity

May 30th 2017

Emergency Management of Chemotherapy Toxicity

May 30th 2017

Severe Early-Onset Toxicities From 5-FU or Capecitabine

May 30th 2017

5-FU or Capecitabine Toxicity Patient Education

May 30th 2017

Chemotherapy Overdose of 5-FU or Capecitabine

May 30th 2017

Nursing Perspective of Early-Onset Severe Toxicities

May 30th 2017

Early-Onset Toxicities from 5-FU and Capecitabine

May 30th 2017

Chemotherapy for Metastatic Colorectal Cancer in 2017

May 30th 2017

Dr. Grothey on FDA Approval of Pembrolizumab in MSI-High CRC

May 24th 2017

Axel Grothey, MD, medical oncologist at Mayo Clinic, discusses the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with microsatellite instability-high colorectal cancer (CRC).

Dr. Sears on Ongoing Research of Microbiota in CRC

May 24th 2017

Cynthia L. Sears, MD, professor of Medicine, at Johns Hopkins University School of Medicine, member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy, discusses ongoing research of microbiota for patients with colorectal cancer (CRC).

FDA Approves Pembrolizumab for Microsatellite Instability-High and Mismatch Repair Deficient Cancers

May 23rd 2017

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed after prior treatment and who have no satisfactory alternative treatment options, as well as for patients with MSI-H or dMMR colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Adopting Healthy Lifestyle Leads to Improved Overall Survival in Postsurgical Colon Cancer

May 18th 2017

Patients with stage III colorectal cancer who maintained a healthy body weight, engaged in regular physical activity, and adopted other healthy lifestyle behaviors experienced a 42% lower chance of death and a trend toward reduced cancer recurrence.

Eating Nuts After Colon Cancer Improves Survival and Lowers Recurrence Risk

May 18th 2017

Findings of a new prospective study suggest that eating tree nuts like almonds, walnuts, and pecans can improve overall survival and reduce the risk of recurrence in patients with colon cancer.

Genomic Findings Reshaping CRC Field

May 16th 2017

Extensive studies into molecular aberrations in colorectal cancer are yielding fresh insights into the potential clinical utility of checkpoint immunotherapies, genetic testing, and tumor-sidedness implications. Experts weigh in on key developments that may change treatment paradigms.

Watch-and-Wait Approach May Be Beneficial for Rectal Cancer Patients

May 12th 2017

Fahima Dossa, MD, discussed the potential of using a watch-and-wait approach in the management of patients with rectal cancer.

Dr. Venook Discusses the Role of Chemotherapy in Metastatic CRC

May 11th 2017

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the role of chemotherapy in metastatic colorectal cancer (CRC).

Researchers Perform First Robotic Colonoscopy

May 9th 2017

Researchers have successfully performed autonomous retroflexion of a robotic capsule during colonoscopy in a subject animal, according to data presented during Digestive Disease Week 2017 at McCormick Place in Chicago.

Dr. Yurgelun Discusses Germline Testing in CRC

May 3rd 2017

Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.

Dr. Shah on the Difference in Treatment of Left- and Right-Sided Tumors in CRC

May 2nd 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses the difference in treatment of left- and right-sided tumors in colorectal cancer.